- Home
- ELBM vs PLRX Comparison
ELBM vs PLRX Comparison
Compare ELBM & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELBM | PLRX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELBM | PLRX |
|---|---|---|
| Price | $0.90 | $1.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 11 |
| Target Price | $2.15 | ★ $3.79 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $1.10 |
| 52 Week High | $8.70 | $15.00 |
Technical Indicators
Market Signals| Indicator | ELBM | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 36.92 |
| Support Level | $0.97 | $1.17 |
| Resistance Level | $1.10 | $1.35 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 6.68 | 21.88 |
Price Performance
Historical ComparisonAbout ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.